As always, MedSIR will be back in Texas at the San Antonio Breast Cancer Symposium.
Always a special time for MedSIR, this year’s SABCS will be extra special since it will represent MedSIR’s first official exposition of its latest potentially ground-breaking clinical trial, the PHERGain Study: “Chemotherapy-free trastuzumab and pertuzumab in HER2- positive breast cancer: FDG-PET response-adapted strategy”.
MedSIR will be presenting a poster outlining the PHERGain study design. After finalizing the PARSIFAL study –a phase II metastatic breast cancer study that just recently terminated its 464-patient enrollment- the PHERGain trial will explore the early breast cancer setting and represent MedSIR’s next large multinational phase II project, spanning a half dozen European countries and accruing 400 patients (enrollment began just a few months ago). The primary objective of PHERGain is to assess the early metabolic effects of neoadjuvant treatment with trastuzumab and pertuzumab ± endocrine therapy according to ER status on the primary tumor and their predictive values for pCR. In other words, the goal is to attempt to identify HER2-positive breast cancer patients who can be cured without the need for chemotherapy.
The study Steering Committee includes Top European Experts in Breast Cancer such as Drs. Serena Di Cosimo, Joseph Gligorov, Peter Schmid, Javier Cortés and Antonio Llombart. Dr. Géraldine Gebhart is on as our Nuclear Medicine Expert. A great team for an even greater study.
Please visit the following link for more information regarding the PHERGain study.